ライフサイエンスコーパス: radiosensitizer

1 a brain-penetrant ATM inhibitor and a potent radiosensitizer.

2 anted side effects when used clinically as a radiosensitizer.

3 sion, indicating the compound functions as a radiosensitizer.

4 idate for further development as a potential radiosensitizer.

5 cancer demonstrating the role of RK-33 as a radiosensitizer.

6 Our studies identify MMAE as a potent radiosensitizer.

7 now shows promise as an anticancer drug and radiosensitizer.

8 super-repressor constructs) to function as a radiosensitizer.

9 ile, either as a chemotherapeutic agent or a radiosensitizer.

10 eta-lap may warrant clinical evaluation as a radiosensitizer.

11 eatment of pancreatic cancer and is a potent radiosensitizer.

12 d who have not received prior cisplatin as a radiosensitizer.

13 sistance, and the EGFR KI GW572016 acts as a radiosensitizer.

14 of the head and neck (SCCHN) and an in vitro radiosensitizer.

15 ting that 6-aminonicotinamide is acting as a radiosensitizer.

16 s an excellent target for the development of radiosensitizers.

17 ribose) polymerase (PARP) inhibitors used as radiosensitizers.

18 anism of Cu-Cy for cancer treatment as a new radiosensitizers.

19 y and the potential use of ATM inhibitors as radiosensitizers.

20 th an emphasis on complexes that function as radiosensitizers.

21 mall peptides as specific ATM inhibitors and radiosensitizers.

22 all molecules that could function as thermal radiosensitizers.

23 d docetaxel are being extensively studied as radiosensitizers.

24 However, using both radiosensitizers, a significantly greater radiosensitiza

25 tter understand the interaction of these two radiosensitizers, additional studies on DNA repair and c

26 b should be considered a potential cutaneous radiosensitizer and an inducer of radiation recall derma

27 rected conjugate, could function as a potent radiosensitizer and be selectively delivered to tumors u

28 poxic cells, which display resistance to the radiosensitizer and IGF1R inhibitor AG1024.

29 Cabazitaxel is a radiosensitizer and may treat PSMA-negative disease that

30 tive component of soy isoflavones, acts as a radiosensitizer and potentiates prostate tumor cell kill

31 ight BET bromodomain inhibitors as potential radiosensitizer and provide a rationale for developing c

32 NP Wtmn was found to be a potent radiosensitizer and was significantly more effective tha

33 articles (NPs) are studied as drug carriers, radiosensitizers and imaging agents, and characterizing

34 iation regimens, the use of new hypoxic cell radiosensitizers and monoclonal antibodies that inhibit

35 As a new type of radiosensitizers and photosensitizers, Cu-Cy nanoparticl

36 hroughput screening method to identify novel radiosensitizers and suggest that NS-123 and similar nit

37 perimental data show that glucoazomycins are radiosensitizers and that they competitively inhibit glu

38 g (177)Lu-PSMA-617 with idronoxil (NOX66), a radiosensitizer, and examine potential clinical, blood-b

39 ted therapeutic compounds, NU7441 - a potent radiosensitizer, and gemcitabine - an FDA approved chemo

40 plore combinations of FU with cisplatin, new radiosensitizers, and active drugs combined with RT to r

41 e have demonstrated that POH is an effective radiosensitizer at clinically relevant doses of radiatio

42 ere selected as candidate Notch-1-regulating radiosensitizers based on the results of assay screening

43 w a significant increase in the ratio of the radiosensitizer bromodeoxyuridine (BUdR) in tumors versu

44 model, we showed that metformin may act as a radiosensitizer by increasing tumor oxygenation and that

45 We concluded that the use of HT as a radiosensitizer can improve the outcome for glioblastoma

46 Here we show that hyperthermia, an effective radiosensitizer, can induce several steps associated wit

47 The hetero-bifunctional nitroimidazole radiosensitizer CI-1010, R-alpha-[[(2-bromoethyl)-amino]

48 cantly more effective than the commonly used radiosensitizer cisplatin in vitro in three cancer cell

49 iosensitization using antibodies to restrict radiosensitizer delivery.

50 nly on physical improvements in delivery, as radiosensitizer development to target tumor cells has ye

51 ) complex may thus be a potential target for radiosensitizer development.

52 atients were given capecitabine therapy as a radiosensitizer (dose 2 g/day) from day 0 to 14 of every

53 easibility of administering carboplatin as a radiosensitizer during craniospinal radiation therapy (C

54 These data support testing of curcumin as a radiosensitizer for the clinical treatment of alveolar r

55 ncept for use of MLN4924 as a novel class of radiosensitizer for the treatment of pancreatic cancer.

56 ial in Europe for potential use as a hypoxia radiosensitizer for treatment of head and neck cancers.

57 -PK inhibitors with significant potential as radiosensitizers for cancer treatment.

58 alignancies, there are no genomically-driven radiosensitizers for clinical use.

59 tal-organic frameworks (nMOFs) are excellent radiosensitizers for radiotherapy via enhanced energy de

60 tal-organic frameworks (nMOFs) are excellent radiosensitizers for radiotherapy-radiodynamic therapy (

61 by the single-agent toxicity of traditional radiosensitizers (for example, platinums) and a lack of

62 larger than that of the most popularly used radiosensitizers, gold nanoparticles (1.19), and paclita

63 ti-cancer agents, but their potential use as radiosensitizers has been neglected so far.

64 particular, the use of biological agents as radiosensitizers has led to the investigation of new com

65 in conjunction with antiandrogens serving as radiosensitizers has utility as a radiotherapeutic agent

66 t clear yet and Cu-Cy nanoparticles as novel radiosensitizers have never been tested on colorectal ca

67 Nitric oxide (NO) is a potent tumor radiosensitizer; however, its clinical use is limited by

68 ext, we have addressed new avenues including radiosensitizers, hypoxia, metabolism, angiogenesis, inv

69 Furthermore, MLN4924 was an effective radiosensitizer in a mouse xenograft model of human panc

70 CRLX101 was evaluated as a radiosensitizer in colorectal cancer cell lines and muri

71 ognized as an effective in vitro and in vivo radiosensitizer in human cancers.

72 ti-alphav integrin monoclonal antibody, is a radiosensitizer in mice with xenograft tumors.

73 oRNA (miR)-24 acts as a tumor suppressor and radiosensitizer in NPC cells and xenografts by targeting

74 nce that MLN4924 can be used as an effective radiosensitizer in pancreatic cancer.

75 carcinoma, we evaluated 2ME2 as a potential radiosensitizer in prostate cancer models.

76 nical utilization of beta-lap (Arq 501) as a radiosensitizer in prostate cancers that overexpress NQO

77 proved drug, nelfinavir, may be an effective radiosensitizer in the clinic.

78 ical utility of pharmacologic ascorbate as a radiosensitizer in the treatment of pancreatic cancer.

79 alternative to intravenous fluorouracil as a radiosensitizer in these patients.

80 Docetaxel was assessed as a radiosensitizer in this situation.

81 support the use of NRP2 mAb as an effective radiosensitizer in TNBC.

82 idine; dFdCyd) has been shown to be a potent radiosensitizer in tumor cells both in vitro and in vivo

83 f NP Wtmn, we evaluated the therapeutic as a radiosensitizer in vitro and in vivo.

84 one (beta-lap; Arq 501), can act as a potent radiosensitizer in vitro through an unknown mechanism.

85 inally, NP Wtmn was shown to be an effective radiosensitizer in vivo using two murine xenograft model

86 therapeutic enhancement of antiandrogens as radiosensitizers in combination with (18)F-FDG in TNBC.

87 al domain (BET) protein inhibitors as potent radiosensitizers in DMG cells.

88 tial development of topoisomerase I drugs as radiosensitizers in treating human malignancies.

89 Caffeine and okadaic acid, both established radiosensitizers, inhibit the incorporation of BrdU in G

90 The use of carboplatin as a radiosensitizer is a promising strategy for patients wit

91 diation that can serve as a highly effective radiosensitizer is reported here, significantly sensitiz

92 The use of gold nanoparticles as radiosensitizers is an effective way to boost the killin

93 Heat is one of the most potent radiosensitizers known.

94 The antimetabolite radiosensitizers may inhibit thymidylate synthase (TS) o

95 ay doses, the intratumoural injection of the radiosensitizer mediated potent outcomes via the repolar

96 nation with checkpoint-blockade therapy, the radiosensitizer mediated the reversal of immunosuppressi

97 We found that a radiosensitizer, myo-inositol trispyrophosphate (ITPP),

98 4'-bromo-3'-nitropropiophenone (NS-123) as a radiosensitizer of human glioma cells in vitro and in vi

99 combination with radiation was an effective radiosensitizer of murine NIH-3T3 fibroblasts, with a se

100 Nitric oxide is a potent radiosensitizer of tumors, but its use clinically is lim

101 on inhibitors may prove clinically useful as radiosensitizers of tumors that depend on ras function.

102 ancer cells and evaluated its potential as a radiosensitizer on cell lines and prostate tumor xenogra

103 esting that carboplatin may be the preferred radiosensitizer, particularly in oropharynx cancers.

104 iodiagnostics, but they are not effective as radiosensitizers/radiochemotherapeutics.

105 with X-ray irradiation and gemcitabine (as a radiosensitizer) strongly suppressed the growth of BAP1-

106 y, and the use of TRT with known or putative radiosensitizers such as poly(adenosine diphosphate ribo

107 inase inhibitors may be more potent cellular radiosensitizers than ATM kinase inhibitors, and that th

108 rove its efficacy through combination with a radiosensitizer that balances therapeutic benefit and to

109 (Cu-Cy) is a new photosensitizer and a novel radiosensitizer that can be activated by light, X-ray an

110 herapeutic relevance of EphB4 targeting as a radiosensitizer that can be exploited for the treatment

111 ngal metabolite, wortmannin, is an effective radiosensitizer that irreversibly inhibits certain membe

112 PS-341 is a potent, selective in vivo radiosensitizer that may substantially affect the effica

113 rhamnetin and cirsiliol can act as promising radiosensitizers that enhance the radiotherapeutic effic

114 Nanoscale radiosensitizers that stimulate anti-tumour immunity and

115 ls, suggesting the role of bicalutamide as a radiosensitizer to (18)F-FDG-mediated radiation damage.

116 G or x-rays, indicating its sensitivity as a radiosensitizer to (18)F-FDG.

117 Adding gemcitabine as a radiosensitizer to 9.25 MBq of PT-RAIT enhanced objectiv

118 Biologically, PD0166285 acts as a radiosensitizer to sensitize cells to radiation-induced

119 therapy relies on tumor-specific delivery of radiosensitizers to attenuate hypoxia resistance.

120 nse Hf(12) secondary building units serve as radiosensitizers to enhance hydroxyl radical generation

121 he mechanistic bases for combining these two radiosensitizers to enhance tumor cytotoxicity.

122 ibited potently by the structurally distinct radiosensitizer, UCN-01.

123 assess the interaction of these two types of radiosensitizers, we compared treatment responses to the

124 ne cancer antigen 19-9, and gemcitabine as a radiosensitizer were associated with a major pathologic

125 vel less than 200 U/mL, and gemcitabine as a radiosensitizer were associated with a major response.

126 rapy, but DA was also equally effective as a radiosensitizer when given only 2 hours before fractiona

127 ely stabilize the nanocomposite and serve as radiosensitizers, whereas the MOF scaffold acts as a con

128 acylpropanediol (SQAP) is a novel veterinary radiosensitizer, which is known to cause angiogenesis al

129 dR) and caffeine are recognized as potential radiosensitizers with different mechanisms of interactio

130 such as the combination of metallo-compound radiosensitizers with radionuclides and within drug deli

131 susceptible to a given molecularly targeted radiosensitizer would be of clinical benefit.